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tion of sub-micron sized particles at body temperature that slowly
resolubilize. This process is associated with a 25-fold increase in
protein half-life in the joint space following intra-articular admin-
istration in a rat model. In this study, a fusion protein of IL1Ra
and ELP was synthesized and demonstrates retention of in vitro
bioactivity for the IL1Ra domain.
Methods: Protein Synthesis. A human IL1Ra gene was fused
to a gene encoding an elastin sequence-containing peptide and
transformed into E. coli for protein expression. Thermal Sensitiv-
ity. Thermal sensitivity of ELP-IL1Ra was evaluated by measuring
solution turbidity and particle sizes below and above the tem-
perature transition by dynamic light scattering. In vitro release
from a thermally transitioned aggregate was quantiﬁed by ab-
sorbance spectrophotometry and compared to non-fusion ELP.
Proteolytic Degradation. In vitro ELP-IL1Ra degradation by col-
lagenase I or II was evaluated by SDS-PAGE after incubation
for 36 hours at 37°C. Fusion Domain Function. An ELISA was
used to quantify the immunoreactivity of ELP-IL1Ra, collage-
nase degradation products, and commercially available rhIL1Ra.
In vitro bioactivity of the fusion protein, collagenase degradation
products, and commercially available IL1Ra was quantiﬁed by
antagonism of IL1 stimulated (2.9 pM) proliferation of RPMI 1788
lymphocytes.
Results: Protein Expression. Fusion of the human IL1Ra to
the desired ELP yielded a 31 kDa chimeric protein. Thermal
Sensitivity. The fusion protein transitioned from monomers of
5 nm radius below 32°C, to supramolecular particles of 129
nm radius at 37°C (Figure 1). Disaggregation at 37°C occurred
with a time constant of 19 h, faster than ELP alone (27 h),
reﬂecting incorporation of the hydrophilic IL1Ra domain. Prote-
olytic Degradation. SDS-PAGE of the collagenase co-incubation
showed disappearance of ELP-IL1Ra and appearance of a 17
kDa fragment (Figure 2). Fusion Domain Function. ELP-IL1Ra
had one-eighth of the immunoreactivity of an equimolar solution
Figure 1. Dynamic light scattering for ELP-IL1Ra at 25 µM shows a transition
from monomers to larger, micron sized aggregates at sub-physiological temper-
atures
Figure 2. SDS-PAGE of ELP-IL1Ra incubation with collagenase II after 36 hours
at 37°C. The 31 kDa protein disappears yielding a 17 KDa fragment.
Figure 3. In vitro bioactivity of ELP-IL1Ra against IL1-induced lymphocite prolif-
eration. The collagenase digest fragment has signiﬁcantly more bioactivity than
the parent fusion protein, approximating that of the commercial protein.
of commercial rhIL1Ra, in contrast to the nearly equivalent im-
munoreactivity of the degradation fragment. ELP-IL1Ra was less
effective in inhibiting lymphocyte proliferation (EC50 310 ± 120
nM) than commercial rhIL1Ra (EC50 1.4 ± 0.3 nM). Bioactivity of
the degradation fragment (EC50 5.0 ± 2.3 nM) was not different
from the commercial antagonist (Figure 3).
Conclusions: Fusion of IL1Ra to ELP creates a thermally-
sensitive protein that can form an in vitro drug depot to sustain
anti-cytokine therapeutic release while preserving partial bioac-
tivity. Administration of ELP-IL1Ra should permit smaller doses
and longer dosing intervals compared to IL1Ra alone. Studies
are needed to determine actual amounts and intervals required
to achieve anti-IL1 effects in an in vivo model of IL1-induced
osteoarthritis.
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Purpose: Several clinical studies demonstrated that Glu-
cosamine Sulfate (GS) is effective in controlling osteoarthri-
tis (OA) symptoms. Moreover, GS seems to have structure-
modifying effects, based on clinical trial data showing that it can
delay radiographic joint space narrowing in knee OA patients.
However, the effects of GS at the tissue level on osteoarthritic ar-
ticular cartilage and other joint structures have not been studied
to date. The STR/ort mice develop a naturally occurring OA of
the tibiofemoral joint, and are therefore believed to be a relevant
model for human knee OA. The purpose of this study was to
investigate the effect of GS on the progression of OA in this
relevant STR/Ort mouse strain model.
Methods: STR/ort male mice were recruited at 6 months of
age (n=20-22/group). One group of animals was sacriﬁced at
this age to serve as a “basal” control. GS was administered
subcutaneously once daily at the doses of 200 and 400 mg/kg:
these doses correspond to 950 and 1900 mg daily in humans,
respectively, after allometric transformation, i.e. they are in line
with the standard oral human dose of 1500 mg once-a-day. After
3 months of daily treatment the animals were euthanized and
the knee joints collected, processed for histology and scored in a
blind fashion according to both Mankin’s (grade) and the OARSI
(grade x stage) method. Furthermore, a histomorphometric anal-
ysis was performed on the medial tibial plateau, measuring the
parameters of cartilage volume, cartilage thickness, rough (dam-
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aged) surface and number of cells, the operator being still blinded
to the treatments.
Results: After three months of daily treatment, we observed that
the vehicle treated animals displayed severe OA with clefting and
erosion of the articular cartilage to the subchondral bone, with
prominent chondro-osseous metaplasias and often inﬂammation
and pannus. However, the OA grade of the tibial medial plateau
was signiﬁcantly decreased in the GS 400 group compared to
vehicle (median grade 2 vs. 5: Figure 1); when examining the OA
grade x stage, administration of both doses of GS was associated
with a signiﬁcant decrease from a median of 16 after vehicle, to
8 and 6 after GS 200 and 400, respectively (Figure 2). Histo-
morphometry showed that the rough surface/total surface ratio
Figure 1. OA grade.
Figure 2. OA grade x stage.
Figure 3. Rough surface/tot surface.
Figure 4. Ncells/volume.
was also decreased in both GS-treated groups compared to ve-
hicle (vehicle 0.79±0.05; GS 200 0.60±0.05; GS400 0.59±0.07,
p<0.05 vs. vehicle for both doses: Figure 3). Furthermore, the
number of viable chondrocytes within the matrix was signiﬁcantly
increased following treatment with GS at both doses (Figure 4).
Despite a similar positive trend, the effect of GS did not reach the
statistical signiﬁcance on the hystomorphometric assessment of
cartilage total volume and thickness.
Conclusions: GS changed the course of OA in the STR/Ort
mouse strain, by delaying cartilage breakdown as assessed his-
tologically and histomorphometrically. We conclude that GS ad-
ministration at human corresponding doses, reduced the severity
of the osteoarthritic pathology in a relevant mouse model.
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Purpose: Vitamin K (VK) has bone and cartilage effects. We
previously demonstrated an association between low VK levels
and radiographic osteoarthritis (ROA), osteophytes (OST), and
joint-space narrowing (JSN) in the hand and knee. However, to
evaluate whether VK might be of therapeutic beneﬁt in OA, a
trial is needed. As part of a RCT of VK supplementation, we
evaluated VK’s effect on hand OA, assuming OA in the hand
is more likely than OA in the knee to be affected by systemic
factors.
Methods: The OA study was ancillary to an ongoing NIH-funded
RCT assessing the effects of VK supplementation (500ug phyllo-
quinone/d vs placebo (PBO)) on bone loss and vascular calciﬁ-
cation among older adults who were not necessarily VK deﬁcient
at baseline (as measured by plasma phylloquinone). Both groups
received vitamin D (400IU) and calcium (600 mg) supplements.
At the ﬁnal 3-year study visit, bilateral hand PA x-rays were
obtained and read for features of OA by a board-certiﬁed MSK
radiologist. We assessed the effects of VK versus PBO on a per-
joint basis for ROA (K/L grade ≥2), JSN (grade ≥2), and OST
(grade ≥2) for all participants, and restricted post-hoc analysis
to the subgroup that had insufﬁcient VK concentrations (≤1nM
based on previous work) at baseline. We also compared the
effects of VK >1nM vs ≤1nM at the ﬁnal study visit in the
whole cohort and in the subgroup with insufﬁcient VK at base-
line. We conducted all analyses intention-to-treat using logistic
regression with GEE to adjust for correlation among joints within
an individual. Analyses were adjusted for age, sex, BMI, smok-
ing status, baseline 25(OH)-vitamin D, education, adherence to
supplements, and baseline physical activity.
Results: Of the 452 participants in the parent study, 378 con-
sented to this ancillary study. 193 were in the active treatment
arm (mean age 70.5 ± 5.5 yrs, 57.5% female, mean BMI 28.5
± 5.4 kg/m2, mean baseline VK 1.27 ± 1.76 nM) and 185 were
in the PBO arm (mean age 70.7 ± 5.5 yrs, 61.6% female, mean
BMI 27.6 ± 4.6 kg/m2, mean baseline VK 1.10 ± 1.40 nM).
There were no effects of randomization to VK for the ROA, JSN,
or OST outcomes (Table 1). In the subgroup that had insufﬁcient
VK at baseline, there were trends towards less radiographic OA
features, with those attaining sufﬁcient concentrations at the ﬁnal
study visit having 47% lower prevalence of JSN (p=0.02) and
22% lower prevalence of ROA (p=0.1).
Conclusions: In this 3-year RCT of VK supplementation in older
adults with and without VK deﬁciency, there was no overall
effect of VK on severity of radiographic hand OA. There was
a suggestion that those with insufﬁcient VK concentrations at
